Current and future treatments for cognitive deficits in dementia.
In this article, we primarily focus on the treatment approaches currently marketed and in advanced stages of development for Alzheimer's disease (AD). Amyloid plaques and neurofibrillary tangles remain the pathologic hallmarks of AD, and much progress has been made in unraveling the molecular biology of these changes. In addition, there is also intense research into inflammatory and oxidative mechanisms as well as vascular and neurochemical alterations in AD. Therapies targeted at these mechanisms are discussed.
McLendon
B M
BM
Duke University Medical Center, Box 3018, Durham, NC 27710, USA. murali@acpub.duke.edu
Chen
G G
GG
Doraiswamy
P M
PM
D000368:Aged; D000544:Alzheimer Disease / Q000150:complications*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D018678:Cholinergic Agents / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D004967:Estrogens / Q000627:therapeutic use; D005544:Forecasting; D020441:Ginkgo biloba / Q000627:therapeutic use; D006801:Humans; D008605:Mental Health Services / Q000639:trends*; D008517:Phytotherapy; D010946:Plants, Medicinal; D014810:Vitamin E / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D018678:Cholinergic Agents; D002800:Cholinesterase Inhibitors; D004967:Estrogens; D014810:Vitamin E